Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;62(6):1583-91.
doi: 10.1002/art.27405.

Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study

Tim Bongartz  1 , Carlotta Nannini, Yimy F Medina-Velasquez, Sara J Achenbach, Cynthia S Crowson, Jay H Ryu, Robert Vassallo, Sherine E Gabriel, Eric L Matteson
Affiliations

Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study

Tim Bongartz et al. Arthritis Rheum. 2010 Jun.

Abstract

Objective: Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD.

Methods: We examined a population-based incidence cohort of patients with RA and a matched cohort of individuals without RA. All subjects were followed up longitudinally. The lifetime risk of ILD was estimated. Cox proportional hazards models were used to compare the incidence of ILD between cohorts, to investigate predictors, and to explore the impact of ILD on survival.

Results: Patients with RA (n = 582) and subjects without RA (n = 603) were followed up for a mean of 16.4 and 19.3 years, respectively. The lifetime risk of developing ILD was 7.7% for RA patients and 0.9% for non-RA subjects. This difference translated into a hazard ratio (HR) of 8.96 (95% confidence interval [95% CI] 4.02-19.94). The risk of developing ILD was higher in RA patients who were older at the time of disease onset, in male patients, and in individuals with more severe RA. The risk of death for RA patients with ILD was 3 times higher than in RA patients without ILD (HR 2.86 [95% CI 1.98-4.12]). Median survival after ILD diagnosis was only 2.6 years. ILD contributed approximately 13% to the excess mortality of RA patients when compared with the general population.

Conclusion: Our results emphasize the increased risk of ILD in patients with RA. The devastating impact of ILD on survival provides evidence that development of better strategies for the treatment of ILD could significantly lower the excess mortality among individuals with RA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incidence of ILD in patient with RA (solid line) and control subjects (broken line)
Figure 2
Figure 2
Survival of RA patients with ILD (solid line) compared to expected survival of RA patients overall (broken line)
See this image and copyright information in PMC

References

    1. Ellman P, Ball RE. Rheumatoid disease with joint and pulmonary manifestations. British medical journal. 1948 Nov 6;2(4583):816–20. - PMC - PubMed
    1. Carmona L, Gonzalez-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Annals of the rheumatic diseases. 2003 Sep;62(9):897–900. - PMC - PubMed
    1. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001 Aug;56(8):622–7. - PMC - PubMed
    1. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. American journal of respiratory and critical care medicine. 1997 Aug;156(2 Pt 1):528–35. - PubMed
    1. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Archives of internal medicine. 2008 Jan 28;168(2):159–66. - PubMed

Publication types

MeSH terms